Elsevier acquires Windhover
This article was originally published in The Rose Sheet
Executive Summary
Elsevier, the parent company of F-D-C Reports, builds upon its array of news and business intelligence services for drug and medical device industries with acquisition of Windhover Information, announced March 10. Elsevier says deal fits with its goal of increasing the "depth and breadth" of offerings that enable informed planning and strategic management. F-D-C Reports publications include "The Rose Sheet," "The Tan Sheet" and "The Pink Sheet," among others. Windhover's businesses include Strategic Transactions Database, a number of drug and device partnering and strategy conferences, and journals IN VIVO and RPM Report. Windhover will operate within Elsevier's Pharma Business Intelligence Unit, which includes Inteleos drug development database as well as F-D-C Reports...